Compound Summary
Compound Information
nevirapine
Compound Name: | nevirapine |
Compound CID: | 4463 |
Synonyms: | nevirapine 129618-40-2 Viramune BI-RG-587 Nevirapine anhydrous More... |
Iupac Name: | 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one |
InChI: | InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20) |
InChIKey: | NQDJXKOVJZTUJA-UHFFFAOYSA-N |
Canonical Smiles: | CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 |
Isomeric Smiles: | CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4 |
Molecular Weight: | 266.3 |
Molecular Formula: | C15H14N4O |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
nevirapine
Molecular Weight: | 266.3 |
Molecular Formula: | C15H14N4O |
Hydrogen Bond Donor Count: | 1 |
Hydrogen Bond Acceptor Count: | 4 |
Rotatable Bond Count: | 1 |
Heavy Atom Count: | 20 |
Complexity: | 397 |
Synonyms
nevirapine
| nevirapine | nevirapine |
|---|---|
nevirapine |
129618-40-2 |
Viramune |
BI-RG-587 |
Nevirapine anhydrous |
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido3,2-b:2,3-e1,4diazepin-6-one |
BIRG 0587 |
NVP |
Viramune XR |
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2,3-e)(1,4)diazepin-6-one |
BI-RG 587 |
UNII-99DK7FVK1H |
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO3,2-B:2,3-E1,4DIAZEPIN-6-ONE |
NSC 641530 |
Nevirapine (Viramune) |
BIRG-0587 |
CHEMBL57 |
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido2,3-e:3,2-b1,4diazepin-6-one" |
11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO3,2-B:2,3-E1,4DIAZEPIN-6(11H)-ONE |
MFCD00866928 |
NEV |
99DK7FVK1H |
MLS000084585 |
CHEBI:63613 |
NSC641530 |
NSC-641530 |
NCGC00065890-02 |
SMR000048458 |
DSSTox_CID_10787 |
DSSTox_RID_78889 |
DSSTox_GSID_31797 |
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo9.4.0.0^{3,8}pentadeca-1(11),3,5,7,12,14-hexaen-10-one |
BIRG587 |
Viramune(TM) |
Viramune (TN) |
CAS-129618-40-2 |
HSDB 7164 |
Nevirapine & CD4-IgG |
Nevirapine & PRO 140 |
Nevirapine (JAN/USP/INN) |
Nevirapine; |
11-cyclopropyl-4-methyl-5H-dipyrido?,?1,4diazepin-6-one |
BIRG 587 |
BIRG-587 |
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE |
11-cyclopropyl-4-methyl-5H-dipyrido2,3-b:3,2-e1,4diazepin-6-one |
Viramune IR |
1vrt |
2hny |
Nevirapine,(S) |
Nevirapine USAN:USP:INN:BAN |
BI-RG-587 & CD4-IgG |
6H-Dipyrido(3,2-b:2,3-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- |
Nevirapine, anhydrous |
Opera_ID_934 |
SCHEMBL3318 |
MLS000759409 |
MLS001055309 |
MLS001201730 |
MLS001424058 |
MLS006011423 |
BIDD:GT0326 |
BDBM1434 |
ZINC4778 |
DTXSID7031797 |
HMS2051J09 |
HMS2231O23 |
HMS3264D21 |
HMS3371E03 |
HMS3393J09 |
HMS3655I08 |
HMS3715B10 |
Pharmakon1600-01503842 |
ALBB-027264 |
BCP05587 |
Tox21 110982 |
Tox21_110982 |
Tox21_200770 |
AC-643 |
AC1280 |
BBL010768 |
NSC759902 |
STK580320 |
AKOS005504351 |
Tox21_110982_1 |
AB07544 |
CCG-100939 |
DB00238 |
KS-5019 |
MCULE-8608154492 |
NC00189 |
NSC-759902 |
NCGC00065890-03 |
NCGC00065890-04 |
NCGC00065890-05 |
NCGC00065890-07 |
NCGC00065890-14 |
NCGC00258324-01 |
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido2,3-e:3,2-b1,4diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody) |
2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo9.4.0.03,8pentadeca-1(11),3,5,7,12,14-hexaen-10-one |
H954 |
HY-10570 |
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido3,2-b:2,3-e-1,4diazepin-6-one & CD4-immunoadhesin |
Nevirapine 100 microg/mL in Acetonitrile |
SY009679 |
BI-RG 587;NSC 641530;NVP |
AB0013383 |
DB-041930 |
FT-0607215 |
FT-0672686 |
N0922 |
S1742 |
SW197569-2 |
C07263 |
D00435 |
AB00393001-13 |
AB00393001-15 |
AB00393001_16 |
AB00393001_17 |
618N402 |
Q263713 |
F2173-0607 |
Z1695906730 |
BI-RG-587; BIRG 0587; BIRG587; HSDB 7164; NSC 641530; NVP |
Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard |
Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard |
Nevirapine solution, 1.0 mg/mL in methanol, certified reference material |
Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material |
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-3,2-b:2,3-e1,4diazepin-6-one" |
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido3,2-b :2,3-e1,4 diazepin-6-one |
11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido3,2-b:2 ,3 -e1,4diazepin-6-one |
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido3,2-b:2, 3-e1,4diazepin-6-one" |
6H-dipyrido2,3-e:3,2-b1,4diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- |
Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard |
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e1,4diazepin-6-one |
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo9.4.0.0^{3,8}pentadeca-1(15),3,5,7,11,13-hexaen-10-one |
Experimental Data
nevirapine
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drosophila melanogaster | 20 | umol/L | 54.37 | 56.54 | 3.99 | NS | FEMALES | 33008901 | Inactive | ||||
| Drosophila melanogaster | 200 | umol/L | 46.39 | 47.1 | 1.54 | NS | MALES | 33008901 | Inactive | ||||
| Caenorhabditis elegans | 10 | umol/L | 16.59 | 16.7 | 0.6173 | NS | N2 | 33008901 | Inactive | ||||
| Caenorhabditis elegans | 100 | umol/L | 16.8 | 15.88 | -5.456 | NS | N2 | 33008901 | Inactive |
Experimental Data Visualization
nevirapine
Statistics Data
nevirapine
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 0.6173 | 1 | 2 | |
| Drosophila melanogaster | 3.99 | 1 | 2 |
Statistics Data Visualization
nevirapine
